A wide range of sensitivities to androgens develops in cloned shionogi mouse mammary tumor cells
- 1 January 1986
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 8 (3) , 293-300
- https://doi.org/10.1002/pros.2990080309
Abstract
Clones obtained in soft agar from a Shionogi mouse mammary carcinoma show marked heterogeneity of growth characteristics and sensitivities to androgens. These data pertain to spontaneous growth in the absence of androgens, maximal response to dihydrotestosterone (DHT) and Km values of the stimulatory action of DHT ranging from 0.008 to 10 ng/ml (1,250‐fold range). Following 13 months in culture in the presence of 10 nM DHT, recloning of one original cell clone led to an even greater variation of androgen‐free growth and of the maximal responses to DHT, while the Km values of DHT action ranged from 0.05 to 10 nM (200‐fold range). The present demonstration of a marked heterogeneity of Km values of DHT action in subpopulations of tumors grown in a controlled environment has major implications for the efficient antihormonal treatment of androgen‐sensitive diseases such as prostate cancer. Such data indicate that cell clones having a high degree of sensitivity to DHT (androgen‐hypersensitive) can continue to grow in the presence of castration levels of androgens, thus suggesting that an antiandrogen is required in order to achieve a more complete androgen blockage and to induce a regression of these androgen‐hypersensitive tumors.Keywords
This publication has 26 references indexed in Scilit:
- Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survivalJournal of Steroid Biochemistry, 1985
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984
- Progression to steroid autonomy in S115 mouse mammary tumor cells: role of DNA methylation.The Journal of cell biology, 1984
- New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgensThe Prostate, 1983
- New Hormonal Therapy in Prostate Cancer: Combined Use of a Pure Antiandrogen and an LHRH AgonistHormone Research, 1983
- Implications of immunological heterogeneity of tumoursNature, 1979
- Reconsideration of Orchiectomy in the Treatment of Advanced Prostatic CarcinomaSouthern Medical Journal, 1977
- Cloned mouse mammary cell lines requiring androgens for growth in cultureCell, 1976
- Adrenal Suppression in the Treatment of Carcinoma of the ProstateBritish Journal of Urology, 1974